East China Pharmaceutical (000963.SZ) subsidiary's clinical trial application for injection HDM2005 approved

Smart Financial News App, Huadong Medicine (000963.SZ) announced that on June 23, 2026, its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceuticals Co., Ltd., received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA) for the clinical trial of injection HDM2005 combined with PD-1 monoclonal antibody and AD (doxorubicin and dacarbazine) for the treatment of classic Hodgkin's lymphoma. This approval marks another significant advancement in the clinical development of HDM2005 in the field of hematologic malignancies, further enhancing the company's core competitiveness in the field of cancer treatment.